AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

After hours: February 7 at 4:50:29 PM EST Loading Chart for OPTN ...

Try Now>> See the top Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE ...

Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.